A Multicenter, Double-blind Study to Evaluate the Effect of Pretreatment With a Daily Dose of Sildenafil on the As-Needed Efficacy of Viagra in Men With Erectile Dysfunction and Type 2 Diabetes
Public ClinicalTrials.gov record NCT00645268. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Double-blind Study to Evaluate the Effect of Pretreatment With a Daily Dose of Viagra® (Sildenafil Citrate) on the PRN Efficacy of Viagra in Men With Erectile Dysfunction and Type 2 Diabetes
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To determine the effect on erectile function in a population of type 2 diabetic men with erectile dysfunction who have undergone the following treatment regimen: pre-treatment with a daily dose of double-blind sildenafil versus placebo for 4 weeks (Phase I) followed by an as-needed, flexible-dose, open-label treatment phase with sildenafil for 12 weeks (Phase II). To assess safety and tolerability of this dosing regimen and to investigate its effects on endothelial function and subject's responses to the Self-Esteem And Relationship (SEAR) questionnaire.
Study identification
- NCT ID
- NCT00645268
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 300 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 35 Years to 70 Years
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 2002 (Type not available)
- Primary completion
- Not listed
- Completion
- Jan 2004 (Actual)
- Last update posted
- Feb 1, 2021
2002 – 2004
United States locations
- U.S. sites
- 28
- U.S. states
- 15
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Huntsville | Alabama | 35801 | — |
| Pfizer Investigational Site | Phoenix | Arizona | 85006 | — |
| Pfizer Investigational Site | Beverly Hills | California | 90212 | — |
| Pfizer Investigational Site | Duarte | California | 91010 | — |
| Pfizer Investigational Site | La Jolla | California | 92037 | — |
| Pfizer Investigational Site | La Jolla | California | 92093 | — |
| Pfizer Investigational Site | Laguna Woods | California | 92653 | — |
| Pfizer Investigational Site | Los Angeles | California | 90048 | — |
| Pfizer Investigational Site | San Diego | California | 92161 | — |
| Pfizer Investigational Site | Norwalk | Connecticut | 06850 | — |
| Pfizer Investigational Site | Waterbury | Connecticut | 06708 | — |
| Pfizer Investigational Site | New Albany | Indiana | 47150 | — |
| Pfizer Investigational Site | Overland Park | Kansas | 66211 | — |
| Pfizer Investigational Site | New Orleans | Louisiana | 70112 | — |
| Pfizer Investigational Site | Baltimore | Maryland | 21224 | — |
| Pfizer Investigational Site | Baltimore | Maryland | 21287 | — |
| Pfizer Investigational Site | Boston | Massachusetts | 02215 | — |
| Pfizer Investigational Site | Minneapolis | Minnesota | 55416 | — |
| Pfizer Investigational Site | Richmond Heights | Missouri | 63117 | — |
| Pfizer Investigational Site | St Louis | Missouri | 63104 | — |
| Pfizer Investigational Site | Buffalo | New York | 14209 | — |
| Pfizer Investigational Site | Medford | Oregon | 97504 | — |
| Pfizer Investigational Site | Portland | Oregon | 97201 | — |
| Pfizer Investigational Site | San Antonio | Texas | 78217 | — |
| Pfizer Investigational Site | San Antonio | Texas | 78229-3894 | — |
| Pfizer Investigational Site | Kirkland | Washington | 98034 | — |
| Pfizer Investigational Site | Tacoma | Washington | 98023 | — |
| Pfizer Investigational Site | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00645268, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 1, 2021 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00645268 live on ClinicalTrials.gov.